Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Key Takeaways A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Long-term health care utilization is greater among patients with COPD who have tested positive for COVID-19 and are unvaccinated.

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

Patients with COPD and established cardiovascular disease have more MACEs and seek less preventive cardiac care than patients with CVD alone.

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Using imaging and respiratory symptoms, researchers identified up to 15.4% of individuals without airflow obstruction as ...